Kowa Co., Ltd has announced the launch in Singapore of GLA-ALPHA® Combination Ophthalmic Solution, a new fixed-dose eye drop licensed from D. Western Therapeutics Institute (DWTI) for the treatment of glaucoma and ocular hypertension.

• Mechanism: The therapy combines ripasudil hydrochloride hydrate, a Rho-kinase inhibitor, with brimonidine tartrate.
• Regulatory Milestone: The product is being marketed in Singapore following DWTI’s licensing agreement with Kowa.
• Application: The fixed combination provides a new treatment option that may improve intraocular pressure control and adherence for patients needing combination therapy.

This summary is based on a press release published on BioSpectrum Asia.